Nautilus, an innovation specialist in home fitness, has entered into a definitive agreement to acquire Zurich based Vay, a company specialising in computer vision and AI technology solutions and the provider of motion detection and
Tags :Vischer
Tvs Motor Company, an Indian based global two-wheeler and three-wheeler manufacturer and the flagship company of the USD 8.5 billion TVS Group, has agreed on a long-term strategic a partnership with Ego Movement, a fast-growing Swiss
Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
Vischer announced the addition of Karin Graf (pictured) to the firm’s litigation and arbitration team, in the role of partner. Graf assumes her new role as of September 1st. Graf brings with her more
Vischer’s dispute resolution team successfully represented a Swiss bank in a multi-faceted conflict, defending against allegations of corruption and breaches of contract as well as massive claims for damages. The dispute included commercial court
Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from
Atlas Antibodies, a global developer of advanced reagents for biomedical research based in Sweden, has agreed to acquire Evitria Group from its shareholders. The transaction closed on August 5, 2021. Vischer advised the sellers on this
